Fig. 2: Impact of the MyCARdiac score and cardiovascular risk on treatment outcomes.

a Definition of the MyCARdiac score components and distribution of high-risk patients. b Correlation matrix of echocardiographic parameters and cardiac biomarkers. c–f Baseline associations of MyCARdiac risk status with sBCMA, EMD, log₂(EASIX), and R-ISS stage. g, h Post-infusion sBCMA and IL-6 levels by risk group. i–l Distribution of early and late N-ICAHT and T-ICAHT scores. m, n Association of MyCARdiac risk with treatment response and CRS grade. o–t Expansion kinetics of total CD3⁺, CD4⁺, and CD8⁺ T-cells and CAR⁺ subsets stratified by risk. u, v Kaplan–Meier curves for PFS and OS according to MyCARdiac (blue) and HFO-ICOS (red) risk classification. HR, 95% CI, and log-rank p-values are shown, and numbers at risk are indicated below each plot. Statistical significance was defined as p < 0.05. Two (c, e, g, h) or one (o–t) sided Mann-Whitney U, chi-square (d, f, i–n), and log-rank (u, v) tests were applied when appropriate.